2026-01-15 - Analysis Report
**Report Overview**
===============

* Overview: **Abbott Laboratories (ABT)**, a multinational medical device and health care company.
* Current Stock Price: $124.985 (last market price)

**Return Analysis**
================

* Review stock (ABT): Cumulative return = 35.30%
* Comparison stock (VOO): Cumulative return = 93.94%
* Divergence = -58.60, relative divergence = 0.30%
* Divergence (max: 37.00, min: -58.90) indicates the current stock is underperforming

**Alpha and Beta Analysis**
==========================

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|-----|-------|-------|--------|
| 2016-2018  | 32.0% | 14.5% | 29.0% | 1.1   | 126.6B |
| 2017-2019  | 41.0% | 14.5% | 24.0% | 1.0   | 152.0B |
| 2018-2020  | -1.0% | 16.8% | -22.0% | 0.9   | 191.6B |
| 2019-2021  | 42.0% | 16.8% | -2.0% | 0.8   | 246.3B |
| 2020-2022  | -20.0% | 28.8% | -18.0% | 0.8   | 192.2B |
| 2021-2023  | -22.0% | 28.8% | -23.0% | 0.7   | 192.6B |
| 2022-2024  | -31.0% | 24.3% | -50.0% | 0.7   | 198.0B |
| 2023-2025  | 10.0% | 16.0% | -52.0% | 0.3   | 219.3B |

* CAGR ranges from 32.0% to -20.0%
* alpha ranges from 29.0% to -52.0%
* Beta ranges from 1.1 to 0.3, indicating increasing volatility

**Recent Stock Price Fluctuations**
---------------------------------

* Close: $124.30
* Last-market: $124.985 (+$0.55)
* MA (5-day, 20-day, 60-day): $125.62, $125.71, $126.17

**Indicators and Signals**
==========================

* Market Risk Indicator (MRI): 0.70
* RSI: 45.95
* PPO: -0.01
* Hybrid Signal: Buy (Cash 0%)
* Recent relative divergence change: -4.50 (worsening)
* 7-day Rank change: 0 (flat)
* 7-day Dynamic Expected Return change: 0.00 (flat)
* Expected Return: -1586.60%

**News and Events**
==================

* Stock Holdings Cut by Exencial Wealth Advisors LLC
* Abbott (ABT) Stock Sinks As Market Gains
* The Bull Case For Abbott Laboratories (ABT)
* 2 Dividend Stocks to Buy for 2026 and Beyond
* Abbott Laboratories Shrugs Off Tariffs & China Headwinds With 7% Dividend Raise

**Analyst Opinions**
==================

* Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.71
- Opinions: 25
- Target Price (avg/high/low): $144.75, $169.00, $122.00

**Recent Earnings Analysis**
==========================

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-29 | 0.94 | 11.37 B$ |
| 2025-07-30 | 1.02 | 11.14 B$ |
| 2025-04-30 | 0.76 | 10.36 B$ |
| 2024-10-31 | 0.94 | 10.63 B$ |

* EPS ranges from 0.76 to 1.02
* Revenue ranges from 10.36 B$ to 11.37 B$

**Financial Information**
=====================

### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.37B | 55.36% |
| 2025-06-30 | $11.14B | 56.44% |
| 2025-03-31 | $10.36B | 56.86% |
| 2024-12-31 | $10.97B | 54.97% |
| 2024-09-30 | $10.63B | 55.83% |

* Revenue ranges from 10.36 B$ to 11.37 B$
* Profit Margin ranges from 54.97% to 56.86%

### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $50.95B | 3.23% |
| 2025-06-30 | $50.56B | 3.52% |
| 2025-03-31 | $48.81B | 2.71% |
| 2024-12-31 | $47.66B | 19.36% |
| 2024-09-30 | $39.80B | 4.14% |

* Equity ranges from $39.80B to $50.95B
* ROE ranges from 2.71% to 19.36%

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.